Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kelsey Woods Morgan"'
Publikováno v:
SAGE Open Medicine, Vol 10 (2022)
Objective: Atogepant is a newly approved medication for the prevention of migraine. This review aims to discuss the efficacy, safety, cost, and place in therapy of atogepant. Methods: The authors performed a systematic search for sources, including a
Externí odkaz:
https://doaj.org/article/0cb415f0e6654f28a3c843d64c0459f9
Autor:
Kelsey Woods Morgan, Kayla Rena Joyner
Publikováno v:
SAGE Open Medicine, Vol 9 (2021)
This article seeks to analyze the clinical trials concerning the newly approved eptinezumab to assess its efficacy, safety, and application to current clinical practice. The Institute of Health US National Library of Medicine Clinical Trials, PubMed,
Externí odkaz:
https://doaj.org/article/76457cda0a3e4d078789c7e01855ed86
Autor:
Kayla Rena Joyner, Kelsey Woods Morgan
Publikováno v:
SAGE Open Medicine, Vol 9 (2021)
SAGE Open Medicine
SAGE Open Medicine
This article seeks to analyze the clinical trials concerning the newly approved eptinezumab to assess its efficacy, safety, and application to current clinical practice. The Institute of Health US National Library of Medicine Clinical Trials, PubMed,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53f497e64a0fc9fd74d93e2272f37bd9
https://pubmed.ncbi.nlm.nih.gov/34659764
https://pubmed.ncbi.nlm.nih.gov/34659764
Publikováno v:
Online Learning. 25
The COVID-19 pandemic required academic institutions to quickly transition to online learning and make changes to assessment procedures. This study examines how a school of pharmacy creatively approached the challenge of online assessment while maint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b5079c90d33eb99c0ca6512d88a795c
https://doi.org/10.24059/olj.v25i1.2580
https://doi.org/10.24059/olj.v25i1.2580
Autor:
Kelsey Woods Morgan, Kayla Rena Joyner
Publikováno v:
The Annals of pharmacotherapy. 55(6)
Objective To review the efficacy, safety, and cost of 3 newly approved agents—ubrogepant, lasmiditan, and rimegepant—representing 2 therapeutic classes, calcitonin gene-related peptide (CGRP) receptor antagonist and serotonin 1F (5-HT1F) agonists
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1d44725483a2ccadb9c1c61d7de83ab
https://pubmed.ncbi.nlm.nih.gov/32993366
https://pubmed.ncbi.nlm.nih.gov/32993366
Publikováno v:
Pharmacology in Clinical Neurosciences ISBN: 9789811535901
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8adc18ad4dd64ab138eb3abb90607e9b
https://doi.org/10.1007/978-981-15-3591-8_1
https://doi.org/10.1007/978-981-15-3591-8_1
